China Heal Plus

HEALTHCARE UPDATE

EMA Recommends Rasonque for Advanced Pancreatic Cancer

By China Heal Plus · Updated

The European Medicines Agency’s human medicines committee recommended Rasonque (daraxonrasib) on October 15 for adults with pancreatic adenocarcinoma that has spread and who have received at least one previous treatment.

The European Review Moves Forward

Rasonque targets RAS proteins involved in cancer growth. EMA assessed the application through a phased review, allowing it to examine data before the complete application was submitted. Its October 15 announcement describes the committee opinion as a step before a European Commission decision on EU marketing authorization. Decisions on price and reimbursement follow at the level of individual member states.

Sources: [1]

An Earlier US Approval

The FDA announced US approval on August 26 for adults with metastatic pancreatic adenocarcinoma after at least one systemic treatment, or for those who cannot receive multiagent systemic therapy. That earlier decision is separate from the new European recommendation.

For a second opinion, our practical takeaway is to include the pathology report and a clear record of previous treatments. Ask the reviewing oncologist how the evidence and local access arrangements apply to the case.

Sources: [2]

Sources and data notes

  1. EMA: Rasonque recommendation for metastatic pancreatic cancer

    EMA news index dates publication October 15, 2026. Original announcement and index checked October 16. Committee recommendation; the notice describes the subsequent Commission and national access steps.

  2. FDA: earlier US Rasonque approval

    Published August 26, 2026; background, not a new October approval. Original checked October 16. Record-preparation suggestions are our editorial interpretation; individual treatment and access require clinical confirmation.

Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.

All healthcare updates